MARKET

GTBP

GTBP

Gt Biopharma Inc
NASDAQ
0.6298
+0.0218
+3.59%
After Hours: 0.6400 +0.0102 +1.62% 19:56 12/04 EST
OPEN
0.6400
PREV CLOSE
0.6080
HIGH
0.6554
LOW
0.5927
VOLUME
1.57M
TURNOVER
--
52 WEEK HIGH
4.100
52 WEEK LOW
0.5400
MARKET CAP
6.70M
P/E (TTM)
-0.1865
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 13h ago
Weekly Report: what happened at GTBP last week (1124-1128)?
Weekly Report · 4d ago
GT Biopharma Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance
Reuters · 11/26 21:31
Weekly Report: what happened at GTBP last week (1117-1121)?
Weekly Report · 11/24 09:11
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/21 21:05
GT Biopharma Advances Potent NK-Cell Therapies As GTB 3650, Is Currently Being Tested In Phase 1 Trials For Patients With Relapsed Or Refractory Acute Myeloid Leukemia
Benzinga · 11/19 13:09
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 11/17 17:06
GT Biopharma (GTBP) Gets a Buy from Roth MKM
TipRanks · 11/17 16:55
More
About GTBP
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Webull offers GT Biopharma Inc stock information, including NASDAQ: GTBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GTBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GTBP stock methods without spending real money on the virtual paper trading platform.